

**Combined analysis of 11 genomewide association studies of bipolar disorder
identifies strong evidence for multiple susceptibility loci**

Authors: Psychiatric GWAS Consortium Bipolar Disorder Working Group

***Full list of authors and affiliations appears at the end of this paper**

Corresponding author: Pamela Sklar (pamela.sklar@mssm.edu)

ABSTRACT

We conducted a combined genome-wide association (GWAS) analysis of 7,481 individuals affected with bipolar disorder and 9,250 control individuals within the Psychiatric Genomewide Association Study Consortium Bipolar Disorder group (PGC-BD). We performed a replication study in which we tested 34 independent SNPs in 4,493 independent bipolar disorder cases and 42,542 independent controls and found strong evidence for replication. In the replication sample, 18 of 34 SNPs had P value < 0.05 , and 31 of 34 SNPs had signals with the same direction of effect ($P = 3.8 \times 10^{-7}$). In the combined analysis of all 63,766 subjects (11,974 cases and 51,792 controls), genome-wide significant evidence for association was confirmed for *CACNA1C* and found for a novel gene *ODZ4*. In a combined analysis of non-overlapping schizophrenia and bipolar GWAS samples we observed strong evidence for association with SNPs in *CACNA1C* and in the region of *NEK4/ITIH1,3,4*. Pathway analysis identified a pathway comprised of subunits of calcium channels enriched in the bipolar disorder association intervals. The strength of the replication data implies that increasing samples sizes in bipolar disorder will confirm many additional loci.

Bipolar disorder (BD) is a severe mood disorder affecting greater than 1% of the population¹. Classical BD is characterized by recurrent manic episodes that often alternate with depression. Its onset is in late adolescence or early adulthood and results in chronic illness with moderate to severe impairment. Although the pathogenesis of BD is not understood, family, twin and adoption studies consistently find relative risks to first-degree relatives of ~8 and concordance of ~40-70% for a monozygotic co-twin^{1,2}. BD shares phenotypic similarities with other psychiatric diseases including schizophrenia (SCZ), major depression and schizoaffective disorder. Relatives of BD individuals are at increased risk of psychiatric phenotypes including SCZ, major depression and schizoaffective disorder, suggesting these disorders have a partially shared genetic basis^{3,4}. Despite robust evidence for a substantial heritability, single causal mutations have not been identified through linkage or candidate gene association studies¹.

Genome-wide association studies (GWAS) for BD have been performed with multiple partially overlapping case and control samples⁵⁻¹¹. In a small study, Baum et al. reported genome-wide significant (defined here as $P < 5 \times 10^{-8}$) association to diacylglycerol kinase eta (*DGKH*)⁵. Subsequently, Ferreira et al.⁸ identified genome-wide significant association in the region of the gene ankyrin 3 (*ANK3*) and Cichon et al.¹² recently reported neurocan (*NCAN*); other studies did not report genome-wide significant loci^{5,9,10,13}. A critical need for psychiatric genetics is to identify consistently associated

loci. Towards that end, the Psychiatric Genome-wide Association Study Consortium (PGC) was established in 2007 to facilitate combination of primary genotype data from studies with overlapping samples and to subsequently allow analyses both within and across the following disorders: autism, attention-deficit hyperactivity disorder, BD, major depressive disorder and SCZ^{14,15}. Here, the Bipolar Disorder Working Group of the PGC reports results from our primary association study of combined data in BD from 16,731 samples, and a replication sample of 47,035 individuals.

We received primary genotype and phenotype data for all samples (Table 1; Supplementary Information and Table S1). Results from sets of samples have been reported singly^{6,7,9-11} and in combinations^{8,9,12} in 7 publications with varying levels of overlap of case and control samples. Data were divided into the 11 case and control groupings shown in Table 1 and each individual was assigned to only one group, with the assignment chosen to maximize power of the combined analysis (See Supplementary Information S2 & S3 for details). The final dataset was comprised of 7,481 unique cases and 9,250 unique controls. Cases had the following diagnoses: BD type 1 (n=6,289; 84%), BD type 2 (n=824; 11%), schizoaffective disorder bipolar type (n=263; 4%), and 104 individuals with other bipolar diagnoses (BD NOS, 1%, Table S1). 46,234 SNPs were directly genotyped by all 11 groups and 1,016,924 SNPs were genotyped by 2-11 groups. Based on reference haplotypes from the HapMap phase 2 CEU sample, genotypes were imputed using BEAGLE¹⁶. We analyzed imputed SNP dosages from 2,415,422 autosomal SNPs with a minor allele frequency (MAF) \geq 1% and imputation quality score $r^2 > 0.3$. We performed logistic regression of case status

on imputed SNP dosage, including as covariates 5 multidimensional scaling components (based on linkage disequilibrium (LD) pruned genotype data, Figure S1) and indicator variables for each sample grouping using PLINK¹⁷. We observed a genomic control¹⁸ value of $\lambda=1.148$. Consistent with previous work suggesting a highly polygenic architecture for SCZ and BD¹⁹, this estimate will likely reflect a mixture of signals arising from a large number of true risk variants of weak effect as well as some degree of residual confounding. Nonetheless, below we designate an association as “genome-wide significant” only if the genomic-control P -value (P_{gc}) is below 5×10^{-8} . Where reported, nominal P -values are labeled P_{raw} . Results for the primary analyses can be found in the supplementary data (Figure S2 (QQ plot); Figure S3 (Manhattan Plot); Figure S4 (Region Plots)), Table S2 lists regions containing an associated SNP with $P_{gc} < 5 \times 10^{-5}$.

Table 2 lists four regions from our primary GWAS analysis that contain SNPs with $P_{raw} < 5 \times 10^{-8}$; two regions reach $P_{gc} \leq 5 \times 10^{-8}$ (see Figure S4 for plots of the regions). Association was detected in ankyrin 3 (*ANK3*) on chromosome 10q21 for the imputed SNP rs10994397 ($P_{gc} = 7.1 \times 10^{-9}$, odds ratio (OR) = 1.35). The second SNP, rs9371601, was located in synaptic nuclear envelope protein 1 (*SYNE1*) on chromosome 6q25 ($P_{raw} = 4.3 \times 10^{-8}$, OR = 1.15). Intergenic SNP rs7296288 ($P_{gc} = 8.4 \times 10^{-8}$; OR = 1.15) is found in a region of LD of ~100 kb on chromosome 12q13 that contains 7 genes. SNP rs12576775 ($P_{gc} = 2.1 \times 10^{-7}$, OR = 1.18) is found at chromosome 11q14 in *ODZ4*, a human homologue of a *Drosophila* pair-rule gene *odz*. Generally consistent signals were observed across studies, with no single study driving

the overall association results (Figure S5). Meta-analysis of the 11 samples under both fixed- and random-effects models yielded results similar to the combined analysis (Table S3 and S4).

We next sought to replicate these findings in independent samples (Table S5). 38 SNPs were selected that had $P_{GC} < 5 \times 10^{-5}$ and were not in LD with each other (Table 3). Of these, four SNPs were not considered to be completely independent signals and are not used for further analyses. (For completeness, data for these 4 SNPs are listed and denoted by an asterisk in Table 3, supplementary Section 6 for details). We received unpublished data from investigators on a further 4,493 cases and 42,542 controls for the top 34 independent SNPs. Significantly more SNPs replicated at all levels than would be expected by chance (Table 3). Four of 34 had P_{rep} values < 0.01 , 18 of 34 SNPs had P_{rep} values < 0.05 and 31 of 34 had signal in the same direction of effect (binomial test, $P = 3.8 \times 10^{-7}$). Within the replication samples, two SNPs remained significant following correction for multiple testing. The first, rs4765913, is found on chromosome 12 in *CACNA1C*, the alpha subunit of the L-type voltage-gated calcium channel ($P_{rep} = 1.6 \times 10^{-4}$, OR = 1.13). The second, rs10896135 is in a 17 exon, 98kb open reading frame C11orf80 ($P_{rep} = 0.0015$, OR = 0.91). Nominally significant P_{rep} values were also obtained in another calcium channel subunit, *CACNB3*. Only 2 of the 4 SNPs in Table 2 had P_{rep} values < 0.05 ; the genome-wide significant SNPs from the primary analysis, rs10994397 and rs9371601 did not ($P_{rep} = 0.11$ and 0.10, respectively). Finally, we performed a fixed-effects meta-analysis, as described in the supplementary information our primary P_{GC} and P_{rep} data and established genome-wide

significant evidence for association with rs4765913 in *CACNA1C* ($P = 1.82 \times 10^{-9}$, OR= 1.14) and rs12576775 in *ODZ4* ($P = 2.77 \times 10^{-8}$; OR = 0.89). As in the primary analyses, generally consistent signals were observed across replication studies and meta-analysis of the replication data also did not reveal significant heterogeneity between the samples (Tables S6 and S7).

To interpret why two of the significant associations in the primary analysis appear to fail to replicate, it is important to quantify the role of the “winner’s curse” on estimates of power to replicate individual signals. Given a polygenic model, power will be very low to detect any one variant at genome-wide significant levels, but there will be many chances to “get lucky” with at least one variant. Those that are discovered will have relatively inflated effect estimates. A simple simulation of the distribution of ORs around several “true” ORs (conditioning on a genome-wide significant P value of 5×10^{-8} , fixed minor allele frequency (0.20), and our sample size (Table S8)) demonstrates a distinct inflation of the estimated OR leading to a marked overestimate of the power to replicate an individual result. For example, for a true genotypic relative risk of 1.05 the mean estimated OR is 1.17, conditioning on having $P < 5 \times 10^{-8}$. Thus, although the nominal power for replication is 100% for the inflated OR, the true power to replicate at $P < 0.05$ is only 30%. Thus any single failure to replicate is by itself less informative. This simulation is consistent with the positive signal we observed in the independent replication where many more than expected show nominal replication with all but one in the original, expected, direction of effect.

We performed an analysis to look for enrichment of Gene Ontology (GO) terms among genes in the association intervals containing the same top 34 independent SNPs used in the replication analysis ($P_{gc} < 5 \times 10^{-5}$) from Table 3 using a permutation-based approach that controlled for potential biases due to SNP density, gene density, and gene size and found enrichment in GO:0015270, dihydropyridine-sensitive calcium channel activity. This GO category contains 8 genes, 3 of which (*CACNA1C*, *CACNA1D* and *CACNB3*) are present among the 34 independent association-intervals tested ($P = 0.00002$); the probability of observing an empirical P value this small, given all the targets tested, is $P = 0.021$ (See Supplementary section 7). Overall, these analyses suggest that the set of intervals ranked highly in our GWAS do not represent a random set with respect to annotated gene function. This analysis focused only on the most significant loci, consistent with the other results presented in this manuscript. It is likely that a study based on a larger number of loci, defined by a more liberal P value cutoff, would indicate other promising areas for biological investigation.

We performed a conditional analysis that included the 34 independent SNPs listed in Table 3. In three of the 34 regions with $P_{gc} < 5 \times 10^{-5}$, we identified SNPs within 1 MB of the most strongly associated SNP that continued to show evidence of association (conditional $P_{gc} < 10^{-4}$). We next performed region specific conditional analysis in these regions and observed conditional association at 3p21.1 (rs736408, conditional $P_{gc} = 8.1 \times 10^{-7}$), 10q21.2 (rs9804190, conditional $P_{gc} = 7.3 \times 10^{-5}$) and 15q14 (rs16966413, conditional $P_{gc} = 7.3 \times 10^{-5}$) (Figure S6). On chromosomes 3 and 15, the SNP most strongly associated after conditioning was > 500 kb from the conditioning SNP with

multiple genes in the intervening interval. On chromosome 10 we observed additional less strongly associated conditionally independent SNPs located upstream of the 5' end of *ANK3*, in an intron of *ANK3*, and at the 3' end of the longest transcript (704kb). In each of these three regions, the association signals remaining after conditioning could arise from multiple causal variants, from a single rare causal variant that is incomplete LD with the tested SNPs or represent false positive associations. The presence of additional SNPs with evidence for association in three of the regions of interest, including *ANK3* (10q21.2) (previously reported by Schulze et al.¹³ in partially overlapping samples), might increase the likelihood that these loci are causal. The 3p21.1 and 15q.14 regions also each showed evidence for association ($P < .05$) in the replication sample for one of the SNPs.

Finally, to provide direct and independent evidence for a highly polygenic basis for BD – as implied by a polygenic component shared between BD and SCZ, International Schizophrenia Consortium (2009) – we repeated the analysis performed by the ISC in these samples, with BD discovery samples. We observed a significant enrichment of putatively-associated BD “score alleles” in target sample cases compared to controls for all discovery P value thresholds tested (see Supplementary Section 9; Table S9).

A parallel study has been performed by the PGC investigators for SCZ. Given the known overlap in risk factors between BD and SCZ, we asked if a combined analysis of PGC-BD and PGC-SCZ (eliminating overlapping control samples, see Supplementary S10 section) would show stronger evidence of association than the original BD GWAS

analysis for 5 of the most strongly associated SNPs from the primary GWAS and meta-analysis, supplemented by the additional genome-wide significant region (i.e. *CACNA1C*) in our replication analyses. In the combined BD and SCZ analysis of GWAS samples two SNPs showed stronger association compared to the BD GWAS analysis, rs4765913 in *CACNA1C* (SCZ $P_{raw} = 7.0 \times 10^{-9}$ compared to BD $P_{raw}=1.35 \times 10^{-6}$) and rs736408 in a multigene region containing *NEK4/ITIH1,3,4* (SCZ $P_{raw} = 8.4 \times 10^{-9}$ compared to BD $P_{raw} = 2.00 \times 10^{-7}$) (Table S10).

In the current analysis of BD we observed primary association signals that reached genome-wide significance ($P_{gc} < 5 \times 10^{-8}$) in the primary analyses in the region of *ANK3* and *SYNE1* and two signals near genome-wide significant on chromosome 12 and in the region of *ODZ4*. While in our independent replication sample we did not find additional support for *ANK3* or *SYNE1*, this is consistent with a potential overestimation of the original ORs and should not be taken to disprove the involvement of these genes. Data from additional samples will be needed to resolve this question.

The most striking finding is the overall abundance of replication signals observed. Among our top 34 signals, the number of nominal associations in the same direction of effect is highly unlikely to be a chance observation. That the enrichment of replication results is almost entirely in the direction of the original observations strongly implies that many, if not most of the signals will ultimately turn out to be true associations with BD. Such results are expected under a highly polygenic model, where there are few or no variants of large effect. BD has a heritability estimated at higher than 80%. As is typical

in studies of complex disorders, our findings explain only a small fraction of this heritability. Our data are consistent with the presence of many common susceptibility variants of relatively weak¹⁹ effect, potentially operating together with rarer variants with a range of effect sizes²⁰. Although this is the largest GWAS study of BD to date, our sample size remains modest in comparison with some other recent meta-analyses of common, complex diseases and is therefore likely to be underpowered to detect the majority of risk variants. Variation among the eleven studies in patient ascertainment, assessment and population could also potentially reduce power to detect loci with relatively specific phenotypic effects. Alternative analytic approaches that consider a broader approach to phenotype, both within and across psychiatric disorders, are underway in the PGC.

In order to understand the implications of these results for disease pathogenesis, we focused on one approach based on the joint analysis of variation at biologically meaningful sets of polymorphisms (e.g. specific genes, gene families or biological pathways). The connections drawn by INRICH between calcium channel subunits are not novel, but are consistent with a prior literature regarding the role of ion channels in BD, the mood stabilizing effects of ion channel modulating drugs, and the specific treatment literature suggesting direct efficacy of L-type calcium channel blockers in the treatment of BD²¹. We observed significant enrichment of *CACNA1C* and *CACNA1D* which are the major L-type alpha subunits found in the brain and their specific association with BD suggests a value to designing calcium channel antagonists that are selective for these subunits. Magnetic resonance imaging studies have implicated

CACNA1C SNP rs1006737 with several alterations in structural²², and functional imaging²³⁻²⁵. Several groups have previously implicated *CACNA1C* in other adult psychiatric disorders, in particular, SCZ and major depression²⁶⁻²⁹. L-type calcium channels also regulate changes in gene regulation responsible for many aspects of neuronal plasticity and have more recently been shown to have direct effects on transcription²⁹. Taken together these lines of evidence should lead to renewed biological investigation of calcium channels in the pathogenesis of BD and other psychiatric diseases. *ODZ4*, located on chromosome 11, is a member of a family of cell surface proteins, the teneurins, related to the *Drosophila* pair-rule gene *ten-m/odz*. These genes are likely involved in cell surface signaling and neuronal pathfinding.

Three of our top 5 regions have non-coding RNAs present within the associated region (none are found in the remaining regions in Table S2). MicroRNAs are small RNA molecules known to regulate gene expression. Mir708, a member of a conserved mammalian microRNA family, is located in the first intron of *ODZ4*. Three small nucleolar RNAs, SNORD69 and SNORD19, and SNORD19B are located on chromosome 3p21.1 and belong to the C/D family of snoRNAs involved in processing and modification of ribosome assembly. Finally, a 121 base non-coding RNA with homology to the 5S-rRNA is also located within the *SYNE1* association region. The role of microRNAs in neurodevelopmental disorders is increasingly apparent in Rett's syndrome, Fragile X and SCZ. Our study represents the first connections to BD.

Our combined analyses with SCZ illuminates the growing appreciation of shared genetic epidemiology³⁰ and shared polygenic contribution to risk³¹. This adds to the evidence that best supported loci have an effect across the traditional bipolar/ schizophrenia diagnostic divide.

In conclusion, we have obtained strong evidence for replication of multiple signals in BD. In particular, we support prior findings in *CACNA1C*, and now identify *ODZ4* as associated with BD. The strongly positive replication results imply that data from additional samples, both from GWAS and sequencing, will identify more of the genetic architecture of BD. When the biological concomitants of the association signals have been characterized they are likely to provide important novel insights into the pathogenesis of BD.

Table 1. Description of individual samples

Sample	Ancestry	Case (n) ^a	Control (n) ^b	Platform ^c	Publication ^d
BOMA- Bipolar Study, University of Bonn and CIMH Mannheim	German	675	1297	550	7-10
Genetic Association Information Network (GAIN) / Bipolar Genome Study (BiGS)	European-American	542	649	6.0	7-10
GlaxoSmithKline (GSK)	British/Canadian/Scottish	890	902	550	9
Pritzker Neuropsychiatric Disorders Research Consortium	European-American	1130	718	550	9
Systematic Treatment Enhancement Program for Bipolar Disorder (STEP1)	European-American	922	645	500K	7,8
Systematic Treatment Enhancement Program for Bipolar Disorder (STEP2)	European-American	659	192	5.0	8
Thematically Organized Psychosis (TOP) Study	Norwegian	203	349	6.0	11
Trinity College Dublin	Irish	150	797	6.0	8
University College London (UCL)	British	457	495	500K	7,8
University of Edinburgh	Scottish	282	275	6.0	8
Wellcome Trust Case-Control Consortium (WTCCC)	British	1571	2931	500K	6,8,9
TOTAL		7481	9250		

^aCases include BD1, BD2, SAB, BD-NOS (see Table S1). ^bMost controls were not screened for psychiatric disease. A subset of 33% however were, see supplement. ^cPlatforms are 6.0 = Affymetrix Genome-Wide Human SNP Array 6.0; 5.0 = Affymetrix Genome-Wide Human SNP Array 5.0; 500K = Affymetrix GeneChip Human Mapping 500K Array; 550 = Illumina HumanHap 550. ^dPrimary publication reporting individual sample level genotypes for BD listed. See supplement for fuller description of publications and table S1 for sample origins in primary GWAS analyses.

Table 2. Primary GWAS association results for four most significant regions

SNP	Chr ^a	Position ^a	Nearest Gene	A1 ^b /A2	A1 freq ^c	OR ^d 95% CI	P_{raw}	P_{gc}
rs10994397	10	61949130	<i>ANK3</i>	T/C	0.06	1.35 (1.48-1.23)	5.5×10^{-10}	7.1×10^{-9}
rs9371601	6	152832266	<i>SYNE1</i>	T/G	0.36	1.15 (1.21-1.10)	4.3×10^{-9}	4.3×10^{-8}
rs7296288	12	47766235	Many	C/A	0.48	1.15 (1.20-1.09)	9.4×10^{-9}	8.4×10^{-8}
rs12576775	11	78754841	<i>ODZ4</i>	G/A	0.18	1.18 (1.25-1.11)	2.7×10^{-8}	2.1×10^{-7}

^aChromosome; ^bSNP basepair position on Build 36; ^cAllele frequency in the total sample; ^dOR is predicted towards allele A1

Table 3. Bipolar association results for primary GWAS, replication and combined samples for the most significant SNP from regions with $P_{gc} < 5 \times 10^{-5}$

SNP	CHR ^b	POS ^c	A1	A2	PRIMARY GWAS		REPLICATION ^a		COMBINED GWAS and REPLICATION		GENES IN LD REGION
					P_{gc}	OR ^d	$P_{1-sided}$	OR	P	OR	
rs4765913	12	2290157	A	T	6.50×10^{-6}	1.15	1.6×10^{-4}	1.13	1.82×10^{-9}	1.14	CACNA1C
rs10896135	11	66307578	C	G	8.46×10^{-6}	0.88	1.47×10^{-3}	0.91	2.77×10^{-8}	0.89	ZDHHC24,YIF1A,TMEM151A, SYT12,SPTBN2,SLC29A2,SF3B2, RIN1,RCE1,RBM4B,RBM4,RBM14, RAB1B,PELI3,PC,PACS1,NPAS4, MRPL11,LRFN4,KLC2,GAL3ST3, DPP3,CTSF,CNIH2,CD248,CCS, CCDC87,C11orf86,C11orf80, BRMS1,BBS1,B3GNT1,ACTN3
rs2070615*	12	47504438	A	G	4.00×10^{-5}	0.90	2.52×10^{-3}	0.93	2.48×10^{-7}	0.91	RND1,DDX23,CACNB3
rs12576775	11	78754841	A	G	2.09×10^{-7}	0.85	7.59×10^{-3}	0.92	6.32×10^{-9}	0.88	ODZ4
rs2175420*	11	78801531	C	T	2.90×10^{-5}	0.87	7.80×10^{-3}	0.92	6.55×10^{-7}	0.89	ODZ4
rs3845817	2	65612029	C	T	1.65×10^{-5}	0.90	8.98×10^{-3}	0.94	4.68×10^{-7}	0.91	
rs2176528	2	194580428	C	G	3.98×10^{-5}	1.15	1.04×10^{-2}	1.09	1.12×10^{-6}	1.12	
rs4660531	1	41612409	G	T	3.16×10^{-5}	0.89	1.11×10^{-2}	0.93	1.02×10^{-6}	0.91	
rs7578035	2	98749324	G	T	1.83×10^{-5}	1.12	1.29×10^{-2}	1.06	7.93×10^{-7}	1.09	TXNDC9,TSGA10,REV1,MRPL30, MITD1,MGAT4A,LYG1,LYG2,LIPT1 ,EIF5B,C2orf55,C2orf15
rs2287921	19	53920084	C	T	1.68×10^{-5}	1.12	1.37×10^{-2}	1.06	8.99×10^{-7}	1.10	SPHK2,SEC1,RPL18,RASIP1, NTN5,MAMSTR,IZUMO1,FUT2, FUT1,FGF21,FAM83E,DBP,CA11
rs11168751*	12	47505405	C	G	1.80×10^{-5}	0.84	1.43×10^{-2}	0.90	7.08×10^{-7}	0.86	CACNB3
rs7296288	12	47766235	A	C	8.39×10^{-8}	0.87	1.50×10^{-2}	0.94	8.06×10^{-9}	0.90	TUBA1B,TUBA1A,RHEBL1, PRKAG1,MLL2,LMBR1L,DHH,DDN
rs7827290	8	142369497	G	T	3.54×10^{-5}	1.13	1.67×10^{-2}	1.06	3.03×10^{-6}	1.10	LOC731779,GPR20
rs12730292	1	79027350	C	G	2.37×10^{-5}	1.12	1.71×10^{-2}	1.06	1.59×10^{-6}	1.10	
rs12912251	15	36773660	G	T	9.57×10^{-6}	1.13	2.04×10^{-2}	1.06	9.63×10^{-7}	1.10	C15orf53
rs4332037	7	1917335	C	T	1.78×10^{-5}	0.87	3.00×10^{-2}	0.93	2.44×10^{-6}	0.90	MAD1L1
rs6550435	3	36839493	G	T	1.97×10^{-5}	1.12	3.26×10^{-2}	1.05	3.26×10^{-6}	1.09	LBA1
rs17395886	4	162498835	A	C	2.18×10^{-5}	0.86	3.51×10^{-2}	0.93	3.78×10^{-6}	0.89	FSTL5
rs6746896	2	96774676	A	G	2.33×10^{-6}	1.14	3.86×10^{-2}	1.05	6.59×10^{-7}	1.10	LMAN2L,FER1L5,CNNM4
rs736408	3	52810394	C	T	1.22×10^{-6}	1.14	4.65×10^{-2}	1.05	6.03×10^{-7}	1.10	WDR82,TWF2,TNNC1,TMEM110, TLR9,STAB1,SPCS1,SNORD69, SNORD19,SNORD19B,SFMBT1, SEMA3G,RFT1,PRKCD,PPM1M, PHF7,PBRM1,NT5DC2,NISCH, NEK4,MUSTN1,LOC440957,ITIH1, ITIH3,ITIH4,GNL3,GLYCTK, GLT8D1,DNAH1,BAP1,ALAS1
rs11162405	1	78242248	A	G	2.54×10^{-5}	0.90	4.76×10^{-2}	0.96	7.11×10^{-6}	0.92	ZZZ3,USP33,NEXN,MGC27382, GIPC2,FUBP1,FAM73A,DNAJB4, AK5
rs9804190	10	61509837	C	T	3.06×10^{-5}	1.17	9.63×10^{-2}	1.04	6.32×10^{-5}	1.10	ANK3
rs9371601	6	152832266	G	T	4.27×10^{-8}	0.87	0.103	0.97	1.52×10^{-7}	0.91	SYNE1
rs3774609	3	53807943	G	T	1.14×10^{-5}	0.89	0.107	0.97	1.63×10^{-5}	0.92	CHDH,CACNA1D
rs10994397	10	61949130	C	T	7.08×10^{-9}	0.74	0.116	0.94	6.14×10^{-8}	0.82	ANK3
rs4668059	2	168874528	C	T	4.45×10^{-5}	1.18	0.158	1.04	7.05×10^{-5}	1.12	STK39
rs16966413	15	36267191	A	G	4.74×10^{-5}	0.84	0.160	0.95	5.10×10^{-5}	0.88	SPRED1
rs6102917	20	40652833	C	G	3.88×10^{-5}	1.44	0.165	1.11	4.22×10^{-5}	1.31	PTPRT
rs11085829	19	13035312	A	G	4.03×10^{-6}	0.87	0.175	0.97	3.37×10^{-5}	0.92	NFIX

Page 17
Revised Draft

rs875326	1	173556022	C	T	2.51×10^{-5}	1.15	0.183	1.03	5.75×10^{-5}	1.10	TNR
rs13245097*	7	2307581	C	T	3.81×10^{-5}	1.13	0.196	1.02	0.0001992	1.08	SNX8,NUDT1,MAD1L1,FTSJ2
rs780148	10	80605089	C	G	4.66×10^{-5}	1.12	0.230	1.03	7.59×10^{-5}	1.09	ZMIZ1
rs2281587	10	105367339	C	T	1.96×10^{-5}	1.12	0.372	1.01	0.000238	1.07	SH3PXD2A,NEURL
rs10776799	1	115674570	G	T	4.84×10^{-5}	1.15	0.434	1.01	0.0009391	1.08	NGF
rs263906	1	101750922	C	T	2.42×10^{-5}	1.13	0.440	1.01	0.0002859	1.08	
rs10028075	4	87186854	C	T	8.96×10^{-6}	0.89	1.00	1.02	0.001651	0.95	MAPK10
rs3968	9	4931997	C	G	2.09×10^{-5}	1.17	1.00	0.92	0.07571	1.04	
rs8006348	14	50595223	A	G	4.91×10^{-5}	0.89	1.00	1.05	0.01855	0.95	TRIM9

^aReplication case and control sample details can be found in the supplement; 4% of the controls were screened for psychiatric disorder^bChromosome; ^cSNP basepair position on Build 36; ^dOR is predicted towards allele A1

Figure 1.





FIGURE LEGENDS:

Figure 1. Results are shown as $-\log_{10}(P \text{ value})$ for genotyped and imputed SNPs. The most associated SNP in the primary analysis is shown as the small purple triangle. The most associated SNP in the combined analysis is shown as the large purple triangle. The color of the remaining markers reflects r^2 with the most associated SNP. The recombination rate from CEU HapMap (second y axis) is plotted in light blue.

AUTHOR LIST:

Manuscript Preparation: Pamela Sklar^{1,2} (chair), Ole A. Andreassen^{3,4}, Sven Cichon^{5,6,7}, Nick Craddock⁸, Howard J. Edenberg⁹, John R. Kelsoe^{10,11}, John I. Nurnberger, Jr.^{12,13}, Shaun Purcell^{1,2}, Marcella Rietschel¹⁴, Stephan Ripke^{1,2}, Laura J. Scott¹⁵

Analysis Group: Shaun Purcell^{1,2} (chair); Members: Douglas Blackwood¹⁶, Aiden Corvin¹⁷, Nick Craddock⁸, Matthew Flickinger¹⁵, Weihua Guan¹⁵, John R. Kelsoe^{10,11}, Morten Mattingsdal³, Andrew McQuillin¹⁸, Phoenix Kwan¹⁵, Stephan Ripke^{1,2}, Laura J. Scott¹⁵, Pamela Sklar^{1,2}, Thomas F. Wienker¹⁹

Central Analysis: Stephan Ripke^{1,2} (chair); Members: Mark Daly^{1,2}, Frank Dudbridge²⁰, Peter A. Holmans²¹, Danyu Lin²²

Management Group: John R. Kelsoe^{10,11} (co-chair), Pamela Sklar^{1,2} (co-chair); Members: Ole A. Andreassen^{3,4}, Douglas Blackwood¹⁶, Margit Burmeister²³, Sven Cichon^{5,6,7}, Nick Craddock⁸, Tiffany A. Greenwood¹⁰, Marian L. Hamshere⁸, Shaun Purcell^{1,2}, Pierandrea Muglia²⁴, John I. Nurnberger, Jr.^{12,13}, Laura J. Scott¹⁵, Erin N. Smith²⁵, Peter P. Zandi²⁶

Data contributed from the following investigators:

BiGS (Bipolar Genome Study) – University California San Diego: John R. Kelsoe^{10,11}, Tiffany A. Greenwood¹⁰, Caroline M. Nievergelt¹⁰, Rebecca McKinney¹⁰, Paul D. Shilling¹⁰; Scripps Translational Science Institute: Nicholas J. Schork²⁷, Erin N. Smith²⁵, Cinnamon S. Bloss²⁵; Indiana University: John I. Nurnberger, Jr.^{12,13}, Howard J. Edenberg⁹, Tatiana Foroud¹², Daniel L. Koller¹²; University of Chicago: Elliot S. Gershon²⁸, Chunyu Liu²⁸, Judith A. Badner²⁸; Rush University Medical Center: William A. Scheftner²⁹; Howard University: William B. Lawson³⁰, Evaristus A. Nwulia³⁰, Maria Hipolito³⁰; University of Iowa: William Coryell³¹; Washington University: John Rice³²; University California San Francisco: William Byerley³³; National Institute Mental Health: Francis J. McMahon³⁴, Thomas G. Schulze^{14, 34, 35}; University of Pennsylvania: Wade Berrettini³⁶, Falk W. Lohoff³⁶; Johns Hopkins Hospital: James B. Potash²⁶, Peter P. Zandi²⁶, Pamela B. Mahon²⁶; University of Michigan: Melvin G. McInnis³⁷, Sebastian Zöllner³⁷, Peng Zhang³⁷; The Translational Genomics Research Institute: David W. Craig³⁸, Szabolcs Szelinger³⁸, Portland Veterans Affairs Medical Center: Thomas B. Barrett³⁹

Central Institute of Mental Health, Mannheim: René Breuer¹⁴, Sandra Maier¹⁴, Marcella Rietschel¹⁴, Thomas G. Schulze^{14, 34, 35}, Jana Strohmaier¹⁴, Stephanie H. Witt¹⁴

GlaxoSmithKline/Institute of Psychiatry/Centre for Addiction & Mental Health/University of Dundee: Federica Tozzi²⁴, Pierandrea Muglia²⁴, Anne Farmer⁴⁰, Peter McGuffin⁴¹, John Strauss⁴², Wei Xu⁴³, James L. Kennedy⁴⁴, John B. Vincent⁴², Keith Matthews⁴⁵, Richard Day⁴⁶

Massachusetts General Hospital: Manuel Ferreira^{1,2}, Colm O-Dushlaine^{1,2}, Roy Perlis^{1,2}, Shaun Purcell^{1,2}, Soumya Raychaudhuri^{1,2}, Douglas Ruderfer^{1,2}, Pamela Sklar^{1,2}, Jordan Smoller^{1,2}

NIMH/Pritzker: Laura J. Scott¹⁵, Matthew Flickinger¹⁵, Margit Burmeister²³, Jun Li²³, Weihua Guan¹⁵, Phoenix Kwan¹⁵, Devin Absher⁴⁷, Robert C. Thompson⁴⁸, Fan Guo Meng⁴⁹, Alan F. Schatzberg⁵⁰, William E. Bunney⁴⁸, Jack D. Barchas⁵¹, Edward G. Jones⁵², Stanley J. Watson⁵³, Richard M. Myers⁴⁷, Huda Akil⁵³, Michael Boehnke¹⁵

Stanley Center Broad Institute: Kim Chambert², Jennifer Moran², Ed Scolnick²

TOP Study Group: Ole A. Andreassen^{3,4}, Srdjan Djurovic^{3,54}, Morten Mattingsdal^{3,55}, Ingrid Melle^{3,4}, Gunnar Morken⁵⁶

Trinity College Dublin: Aiden Corvin¹⁷, Michael Gill¹⁷, Derek Morris¹⁷, Emma Quinn¹⁷

University of Bonn: Sven Cichon^{5,6,7}, Thomas W. Mühleisen⁵, Franziska Degenhardt⁵, Manuel Mattheisen^{5,19}, Johannes Schumacher⁵, Wolfgang Maier⁵⁷, Michael Steffens⁵, Thomas F. Wienker¹⁹, Peter Propping⁵, Markus M. Nöthen⁵

University College London: Adebayo Anjorin¹⁸, Nick Bass¹⁸, Hugh Gurling¹⁸, Radhika Kandaswamy¹⁸, Jacob Lawrence¹⁸, Andrew McQuillin¹⁸

University of Edinburgh: Douglas Blackwood¹⁶, Kevin McGhee¹⁶, Andrew McIntosh¹⁶, Alan W. McLean¹⁶, Walter J. Muir¹⁶, Benjamin S. Pickard¹⁶

Wellcome Trust Case Control Consortium Bipolar Disorder Group – Aberdeen: Gerome Breen^{40,41}, David St. Clair⁴¹; Birmingham: Sian Caesar⁵⁷, Katherine Gordon-Smith^{8,58}, Lisa Jones⁵⁸; Cardiff: Christine Fraser⁸, Elaine K. Green⁸, Detelina Grozeva⁸, Marian L. Hamshere⁸, Peter A. Holmans⁸, Ian R. Jones⁸, George Kirov⁸, Valentina Moskvina⁸, Ivan Nikolov⁸, Michael C. O'Donovan⁸, Michael J. Owen⁸, Nick Craddock⁸; London: David A Collier⁴⁰, Amanda Elkin⁴⁰, Anne Farmer⁴⁰, Richard Williamson⁴⁰, Peter McGuffin⁴⁰; Newcastle: Allan H Young^{45,59}, I. Nicol Ferrier⁴⁵

FOR THE REPLICATION SAMPLES:

Central Institute of Mental Health, Mannheim: René Breuer¹⁴, Sandra Maier¹⁴, Marcella Rietschel¹⁴, Thomas G. Schulze^{14,34,35}, Jana Strohmaier¹⁴, Stephanie H. Witt¹⁴

deCODE Genetics: Kari Stefansson⁶⁰, Hreinn Stefansson⁶⁰, Þorgeir Þorgeirsson⁶⁰, Stacy Steinberg⁶⁰, Ómar Gustafsson⁶⁰

FaST: Sarah E. Bergen¹, Kim Chambert^{1,2}, Jennifer Moran^{1,2}, Vishwajit Nimgaonkar⁶¹, Shaun Purcell^{1,2}, Pamela Sklar^{1,2}, Jordan Smoller^{1,2}

ICCBD: Christina Hultman⁶², Mikael Landén^{62, 63}, Paul Lichtenstein⁶², Patrick Sullivan⁶⁴, Martin Schalling⁶⁵, Urban Osby⁶⁵, Lena Backlund⁶⁶, Louise Frisé⁶⁵, Sarah E. Bergen¹, Shaun Purcell^{1,2}, Kim Chambert^{1,2}, Jennifer Moran^{1,2}, Niklas Langstrom⁶³, Pamela Sklar^{1,2}

INSERM U955: Stéphane Jamain⁶⁷, Marion Leboyer⁶⁷, Bruno Etain⁶⁷, Frank Bellivier⁶⁷

Landspítali University: Hannes Petursson⁶⁸, Engilbert Sigurðsson⁶⁸

Max Planck Institute of Psychiatry, Munich: Bertram Müller-Mysok⁶⁹, Susanne Lucae⁶⁹

Psychiatric Center Nordbaden: Markus Schwarz⁷⁰

Prince of Wales Medical Institute, and University of New South Wales: Peter R. Schofield⁷¹

Queensland Institute of Medical Research: Nick Martin⁷², Grant W. Montgomery⁷²

Centre National de Génotypage: Mark Lathrop⁷³

Therapeia University Hospital, Reykjavík: Högni Óskarsson⁷⁴

University of Bonn: Sven Cichon^{5, 6, 7}, Thomas W. Mühleisen⁵, Franziska Degenhardt⁵, Manuel Mattheisen^{5, 19}, Johannes Schumacher⁵, Wolfgang Maier⁵⁷, Michael Steffens¹⁹, Thomas F. Wienker¹⁹, Peter Propping⁵, Markus M. Nöthen⁵

University of Dresden: Michael Bauer⁷⁵

University of New South Wales and Black Dog Institute: Adam Wright⁷⁶, Philip B. Mitchell⁷⁶

University of Tübingen: Martin Hautzinger⁷⁷

University of Würzburg: Andreas Reif⁷⁸

¹ Psychiatric and Neurodevelopmental Genetics Unit, Department of Psychiatry and Center for Human Genetic Research, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA

² Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA

³ Institute of Clinical Medicine, ENBREC Group, University of Oslo, N-0407 Oslo, Norway

⁴ Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway

⁵ Institute of Human Genetics, University of Bonn, D-53127 Bonn, Germany

⁶ Department of Genomics, Life & Brain Center, University of Bonn, D-53127 Bonn, Germany

- ⁷ Institute of Neuroscience and Medicine (INM-1), Research Center Juelich, D-52425, Juelich, Germany
- ⁸ MRC Centre for Neuropsychiatric Genetics and Genomics, Henry Wellcome Building, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK
- ⁹ Department of Biochemistry and Molecular Biology, Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
- ¹⁰ Department of Psychiatry, University California San Diego, La Jolla, CA 92093, USA
- ¹¹ Department of Psychiatry, Special Treatment and Evaluation Program (STEP), Veterans Affairs San Diego Healthcare System, San Diego, CA 92161, USA
- ¹² Department of Psychiatry, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
- ¹³ Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
- ¹⁴ Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health Mannheim, University Heidelberg, J5, 68159 Mannheim, Germany
- ¹⁵ Department of Biostatistics and Center for Statistical Genetics, School of Public Health, University of Michigan, Ann Arbor, Michigan 48109, USA
- ¹⁶ Division of Psychiatry, University of Edinburgh, Royal Edinburgh Hospital, Edinburgh, EH10 5HF, UK and Medical Genetics Section, University of Edinburgh Molecular Medicine Centre, Western General Hospital, Crewe Road, Edinburgh EH4 2XU, UK
- ¹⁷ Neuropsychiatric Genetics Research Group, Department of Psychiatry and Institute of Molecular Medicine, Trinity College Dublin, Dublin 2, Ireland
- ¹⁸ Molecular Psychiatry Laboratory, Research Department of Mental Health Sciences, University College London, Rockefeller Building, 21 University Street, London, WC1E 6JJ, UK
- ¹⁹ Institute for Medical Biometry, Informatics and Epidemiology, University of Bonn, D-53127 Bonn, Germany
- ²⁰ London School of Hygiene & Tropical Medicine, University of London, London WC1E 7HT, UK
- ²¹ Biostatistics and Bioinformatics Unit, Cardiff University School of Medicine, Cardiff CF14 4XN, UK
- ²² Department of Biostatistics, University of North Carolina, Chapel Hill, North Carolina 27599, USA
- ²³ Departments of Human Genetics and Psychiatry, and Molecular and Behavioral Neuroscience Institute, University of Michigan, Ann Arbor, Michigan 48109, USA
- ²⁴ Neurosciences Centre of Excellence in Drug Discovery, GlaxoSmithKline Research and Development, Verona, Italy
- ²⁵ The Scripps Translational Science Institute and Scripps Health, La Jolla, CA 92037, USA
- ²⁶ Department of Mental Health, Johns Hopkins University and Hospital, Baltimore, Maryland 21287, USA
- ²⁷ The Scripps Translational Science Institute and The Scripps Research Institute, La Jolla, California 92037, USA
- ²⁸ Department of Psychiatry, University of Chicago, Chicago, Illinois 60637, USA
- ²⁹ Rush University Medical Center, Chicago, Illinois 60612, USA
- ³⁰ Department of Psychiatry and Behavioral Sciences, Howard University College of Medicine, Washington, D.C. 20060, USA
- ³¹ Department of Psychiatry, University of Iowa, Iowa City, Iowa 52242, USA
- ³² Washington University School of Medicine, St. Louis, Missouri 63110, USA
- ³³ Department of Psychiatry, University California San Francisco School of Medicine, San Francisco, California 94143, USA
- ³⁴ National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20892, USA
- ³⁵ Department of Psychiatry, University Göttingen, 37075 Göttingen, Germany
- ³⁶ Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
- ³⁷ Department of Psychiatry, University of Michigan, Ann Arbor, Michigan 48109, USA
- ³⁸ The Translational Genomics Research Institute, Phoenix, Arizona 85004, USA
- ³⁹ Portland Veterans Affairs Medical Center, Portland, Oregon 97239, USA
- ⁴⁰ SGDP, The Institute of Psychiatry, King's College London, De Crespigny Park Denmark Hill London SE5 8AF, UK
- ⁴¹ University of Aberdeen, Institute of Medical Sciences, Foresterhill, Aberdeen, AB25 2ZD, UK
- ⁴² Molecular Neuropsychiatry and Development Laboratory, Centre for Addiction and Mental Health, Toronto, Ontario M5S 2S1
- ⁴³ Department of Biostatistics, Princess Margaret Hospital, Toronto
- ⁴⁴ Psychiatric Neurogenetics Section, Centre for Addiction and Mental Health, Toronto, Ontario M5T 1R8

- ⁴⁵ University of Dundee School of Medicine, Nethergate, Dundee, DD1 4HN, Scotland, UK
- ⁴⁶ School of Neurology, Neurobiology and Psychiatry, Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne, NE1 4LP, UK
- ⁴⁷ HudsonAlpha Institute for Biotechnology, Huntsville, Alabama 35806, USA
- ⁴⁸ Department of Psychiatry and Human Behavior, University of California, Irvine, California 92697, USA
- ⁴⁹ Department of Psychiatry, Weill Medical College, Cornell University, New York, New York 10065, USA
- ⁵⁰ Psychiatry and Behavioral Science, Stanford University School of Medicine, Palo Alto, California 94305, USA
- ⁵¹ Institute of Psychiatry, King's College London, University of London SE5 8AF UK
- ⁵² Department of Psychiatry and Behavioral Sciences, Center for Neuroscience, University of California, Davis, California 95618, USA
- ⁵³ Molecular and Behavioral Neuroscience Institute, University of Michigan, Ann Arbor, Michigan 48109, USA
- ⁵⁴ Department of Medical Genetics, Oslo University Hospital, Oslo, Norway
- ⁵⁵ Department of Research, Soerlandet Hospital, Kristiansand, Norway
- ⁵⁶ Department of Psychiatry, St Olavs Hospital and Norwegian University of Science and Technology, Trondheim, Norway
- ⁵⁷ Department of Psychiatry, University of Bonn, D-53127 Bonn, Germany
- ⁵⁸ Department of Psychiatry, School of Clinical & Experimental Medicine, Birmingham University, Birmingham, B15 2QZ, UK
- ⁵⁹ UBC Institute of Mental Health, 430-5950 University Boulevard Vancouver, British Columbia, Canada V6T 1Z3
- ⁶⁰ deCODE Genetics, University Hospital, Reykjavík, IS-101 Reykjavik, Iceland
- ⁶¹ Department of Human Genetics, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, USA
- ⁶² Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, SE-171 77 Stockholm, Sweden
- ⁶³ Institute of Neuroscience and Physiology, University of Gothenburg, SE-405 30 Gothenburg, Sweden
- ⁶⁴ Department of Genetics, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina 27599, USA
- ⁶⁵ Department of Molecular Medicine, Karolinska Institutet, SE-171 77 Stockholm, Sweden
- ⁶⁶ Department of Clinical Neuroscience, Karolinska Institutet, SE-171 77 Stockholm, Sweden
- ⁶⁷ INSERM U955, ENBREC Group, Department of Psychiatry, Groupe Hospitalier Henri Mondor-Albert Chenevier, AP-HP; Université Paris Est, Fondation FondaMental, Créteil 94000, France
- ⁶⁸ Division of Psychiatry, Landspítali University Hospital, IS-101 Reykjavik, Iceland
- ⁶⁹ Max Planck Institute of Psychiatry, Munich, Germany
- ⁷⁰ Psychiatric Center Nordbaden, Wiesloch, Germany
- ⁷¹ Prince of Wales Medical Institute, Sydney, Australia, and University of New South Wales, Sydney, Australia
- ⁷² Queensland Institute of Medical Research, Brisbane, Australia
- ⁷³ Centre National de Génotypage, Evry, France
- ⁷⁴ Therapeia, University Hospital, Reykjavík, IS-101 Reykjavik, Iceland
- ⁷⁵ Department of Psychiatry and Psychotherapy, ENBREC Group, University Hospital Carl Gustav Carus, Dresden, Germany
- ⁷⁶ School of Psychiatry, University of New South Wales and Black Dog Institute, Sydney, New South Wales, Australia
- ⁷⁷ Department of Clinical and Developmental Psychology, Institute of Psychology, University of Tübingen, Tübingen, Germany
- ⁷⁸ Department of Psychiatry, University of Würzburg, Würzburg, Germany

ACKNOWLEDGEMENTS

We would like to recognize the contribution of thousands of subjects without whom this work would not be possible. Thomas Lehner (NIMH) was instrumental in initiating and planning the overall project. Daniella Posthuma and the Dutch Genetic Cluster Computer provided invaluable computational resources. We also thank the PGC schizophrenia group for allowing us to perform the combined analyses of 6 loci prior to publication. This work was supported by many grants from NIH (MH078151, MH081804, MH059567 supplement, MH59553, MH080372, 1U54RR025204). Other sources of support include: the Genetic Association Information Network (GAIN), the NIMH Intramural Research Program, the Tzedakah Foundation, the American Philosophical Society, the Stardust foundation, the National Library of Medicine, the Stanley Foundation for Medical Research, and the Wellcome Trust, the Pritzker Neuropsychiatric Disorders Research Fund L.L.C., GlaxoSmithKline, as well as grants for individual studies (see supplemental acknowledgements). TOP Study was supported by grants from the Research Council of Norway (167153/V50, 163070/V50, 175345/V50) and South-East Norway Health Authority (123-2004), and EU (ENBREC).

Protocols and assessment procedures were approved by the relevant ethical review mechanisms for each study. All participants provided written informed consent prior to participation in the primary study and consent allowed the samples to be used within the current combined analyses. Genotype data from this manuscript for 10,257 samples can be obtained from the Center on Collaborative Genetic Studies of Mental Disorders

in accordance with NIMH data release policies (<http://zork.wustl.edu/nimh/>). Genotype data from the WTCCC sample can be obtained from https://www.wtccc.org.uk/info/access_to_data_samples.shtml. Genotype data from the BOMA-Bipolar Study can be obtained by contacting S. Cichon directly (sven.cichon@uni-bonn.de).

COMPETING FINANCIAL STATEMENT

We have no competing financial interests.

DATA RELEASE POLICY

Data will be released through the NIMH Genetics Initiative Repository.

REFERENCES

1. Craddock, N. & Sklar, P. Genetics of bipolar disorder: successful start to a long journey. *Trends Genet* **25**, 99-105 (2009).
2. Cardno, A.G. *et al.* Heritability estimates for psychotic disorders: the Maudsley twin psychosis series. *Arch Gen Psychiatry* **56**, 162-8 (1999).
3. Craddock, N. & Jones, I. Genetics of bipolar disorder. *J Med Genet* **36**, 585-94 (1999).
4. Craddock, N., O'Donovan, M.C. & Owen, M.J. The genetics of schizophrenia and bipolar disorder: dissecting psychosis. *J Med Genet* **42**, 193-204 (2005).
5. Baum, A.E. *et al.* A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder. *Mol Psychiatry* (2007).
6. WTCCC. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. *Nature* **447**, 661-78 (2007).
7. Sklar, P. *et al.* Whole-genome association study of bipolar disorder. *Mol Psychiatry* **13**, 558-69 (2008).
8. Ferreira, M.A. *et al.* Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. *Nat Genet* (2008).
9. Scott, L.J. *et al.* Genome-wide association and meta-analysis of bipolar disorder in individuals of European ancestry. *Proc Natl Acad Sci U S A* **106**, 7501-6 (2009).
10. Smith, E.N. *et al.* Genome-wide association study of bipolar disorder in European American and African American individuals. *Mol Psychiatry* **14**, 755-63 (2009).
11. Djurovic, S. *et al.* A genome wide association study of bipolar disorder in Norwegian individuals, followed by replication in Icelandic sample. *J Affect Disord* *in press*. (2010).
12. Cichon, S. Genome-wide association study identifies genetic variation in neurocan as a susceptibility factor for bipolar disorder. *Am J Hum Genet* (in press).
13. Schulze, T.G. *et al.* Two variants in Ankyrin 3 (ANK3) are independent genetic risk factors for bipolar disorder. *Mol Psychiatry* **14**, 487-91 (2009).
14. PGC. A framework for interpreting genome-wide association studies of psychiatric disorders. *Mol Psychiatry* **14**, 10-7 (2009).
15. Cichon, S. *et al.* Genomewide association studies: history, rationale, and prospects for psychiatric disorders. *Am J Psychiatry* **166**, 540-56 (2009).
16. Browning, S.R. & Browning, B.L. Rapid and accurate haplotype phasing and missing-data inference for whole-genome association studies by use of localized haplotype clustering. *Am J Hum Genet* **81**, 1084-97 (2007).
17. Purcell, S. *et al.* PLINK: A Tool Set for Whole-Genome Association and Population-Based Linkage Analyses. *Am J Hum Genet* **81**, 559-75 (2007).
18. Devlin, B. & Roeder, K. Genomic control for association studies. *Biometrics* **55**, 997-1004. (1999).

19. ISC. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. *Nature* **460**, 748-52 (2009).
20. Zhang, D. *et al.* Singleton deletions throughout the genome increase risk of bipolar disorder. *Mol Psychiatry* **14**, 376-80 (2009).
21. Levy, N.A. & Janicak, P.G. Calcium channel antagonists for the treatment of bipolar disorder. *Bipolar Disord* **2**, 108-19 (2000).
22. Kempton, M.J. *et al.* Effects of the CACNA1C risk allele for bipolar disorder on cerebral gray matter volume in healthy individuals. *Am J Psychiatry* **166**, 1413-4 (2009).
23. Krug, A. *et al.* Effect of CACNA1C rs1006737 on neural correlates of verbal fluency in healthy individuals. *Neuroimage* **49**, 1831-6.
24. Bigos, K.L. *et al.* Genetic variation in CACNA1C affects brain circuitries related to mental illness. *Arch Gen Psychiatry* **67**, 939-45.
25. Erk, S. *et al.* Brain function in carriers of a genome-wide supported bipolar disorder variant. *Arch Gen Psychiatry* **67**, 803-11.
26. Nyegaard, M. *et al.* CACNA1C (rs1006737) is associated with schizophrenia. *Mol Psychiatry* **15**, 119-21.
27. Curtis, D. *et al.* Case-case genome-wide association analysis shows markers differentially associated with schizophrenia and bipolar disorder and implicates calcium channel genes. *Psychiatr Genet* **21**, 1-4.
28. Green, E.K. *et al.* The bipolar disorder risk allele at CACNA1C also confers risk of recurrent major depression and of schizophrenia. *Mol Psychiatry* (2009).
29. Gomez-Ospina, N., Tsuruta, F., Barreto-Chang, O., Hu, L. & Dolmetsch, R. The C terminus of the L-type voltage-gated calcium channel Ca(V)_{1.2} encodes a transcription factor. *Cell* **127**, 591-606 (2006).
30. Lichtenstein, P. *et al.* Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. *Lancet* **373**, 234-9 (2009).
31. International Schizophrenia Consortium. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. *Nature* **460**, 748-52 (2009).